Medera's Heart Gene Therapy Clears Key Hurdle in Quest to Treat HFpEF

BOSTON – June 25, 2026 – In the high-stakes world of biotechnology, a nod from an independent watchdog can be as valuable as a billion-dollar investment. Today, Medera Inc. received just that, announcing that an independent Data Monitoring Committee (DMC) has given the green light for its pioneering gene therapy trial to proceed without changes. The decision is a critical vote of confidence in the company’s lead program, SRD-002, a potential disease-modifying therapy for one of cardiology’s most formidable challenges: heart failure with preserved ejection fraction (HFpEF).

Following a scheduled review of safety and clinical data from the ongoing MUSIC-HFpEF study, the panel of independent experts found no safety concerns that would require modifying the trial. For Medera, this recommendation is more than a procedural step; it is a significant de-risking event that validates the safety of its approach and strengthens its position as it prepares for pivotal discussions with the U.S. Food and Drug Administration (FDA).

Tackling an Unmet Need in Cardiology

Heart failure is a global epidemic affecting over 64 million people, and HFpEF accounts for roughly half of those cases. Unlike its counterpart, heart failure with reduced ejection fraction (HFrEF), where the heart muscle is too weak to pump efficiently, HFpEF patients have a heart that pumps normally but is too stiff to relax and fill properly. This leads to a dangerous backup of pressure in the heart and lungs, causing debilitating symptoms, frequent hospitalizations, and a mortality rate comparable to many cancers.

For decades, physicians had few effective tools for HFpEF. While recent breakthroughs with SGLT2 inhibitors and other drug classes have improved symptoms and reduced hospitalizations, they don't fix the fundamental problem in the heart muscle. A truly disease-modifying therapy that targets the root cause has remained the field's holy grail.

This is the gap Medera aims to fill. SRD-002 isn’t another pill to manage symptoms; it’s a one-time gene therapy designed to repair the cellular machinery behind the disease.

Fixing the Engine: The Science of SRD-002

At the heart of Medera’s therapy is a protein called SERCA2a. In a healthy heart, SERCA2a acts like a pump, rapidly moving calcium ions back into storage within heart cells (cardiomyocytes) during the relaxation phase of a heartbeat. In HFpEF, the expression and function of SERCA2a are impaired. This leads to a buildup of calcium, preventing the heart muscle from relaxing properly and causing the characteristic stiffness of the disease.

SRD-002 uses a well-understood and non-pathogenic adeno-associated virus (AAV1) as a delivery vehicle to introduce a healthy copy of the SERCA2a gene directly into heart cells. The goal is to restore the cell's ability to handle calcium correctly, thereby improving relaxation, reducing stiffness, and normalizing cardiac function.

“We are very encouraged by the outcome of this independent DMC review,” said Ronald Li, PhD, Chief Executive Officer and Founder of Medera, in the company's press release. “We believe this outcome further supports the favorable safety profile observed to date and provides additional confidence as we prepare for the next stage of randomized study.”

Adding to the innovation is Medera's delivery method. Instead of a systemic intravenous infusion that floods the body with the viral vector, SRD-002 is administered via a minimally invasive catheter directly into the coronary arteries. This targeted approach is designed to maximize gene transfer to the heart while minimizing systemic exposure, a key safety consideration in gene therapy.

A Critical Milestone: Decoding the DMC's Green Light

A Data Monitoring Committee operates as the conscience of a clinical trial. This independent group of experts gets an unblinded look at all the accumulating data, with the primary mandate to protect patient safety. A recommendation to continue a trial “without modification” is the best-case scenario, signaling that the therapy is behaving as expected and not producing unforeseen safety issues.

This endorsement is particularly powerful because the DMC reviewed comprehensive data from the ten patients treated so far across two dose cohorts. According to Medera, no gene therapy-related serious adverse events have been reported. Furthermore, the committee's decision was informed by encouraging early clinical signals. As reported at the 2025 American Heart Association Scientific Sessions, patients in the first cohort showed improvements in functional capacity (NYHA class), quality of life (KCCQ scores), and a key hemodynamic measure called pulmonary capillary wedge pressure (PCWP)—a direct indicator of pressure in the heart that is a hallmark of HFpEF.

“HFpEF remains one of the largest unmet needs in cardiovascular medicine,” Dr. Li added. “This independent DMC recommendation represents an important clinical and regulatory de-risking milestone as we continue preparing for randomized development and future FDA interactions.”

Navigating the Path Forward

The positive DMC review provides a tailwind not just for the HFpEF program, but for Medera's entire cardiovascular gene therapy platform. The committee also completed a safety review of the company's separate trial for HFrEF, again finding no safety concerns and allowing the randomized Phase 2b study to continue.

“The independent DMC reviews across both our HFpEF and randomized HFrEF programs provide encouraging support for the safety profile observed to date with our cardiovascular gene therapy platform,” noted Roger J. Hajjar, MD, President and Chief Medical Officer of Medera.

With this milestone secured, Medera's focus now shifts to completing long-term follow-up for its MUSIC-HFpEF trial, with 12-month data from the second, higher-dose cohort expected in the last quarter of 2026. The company will then move toward designing a larger, randomized clinical trial—the kind of study required for eventual FDA approval. For the millions of patients living with the burden of HFpEF, Medera's progress represents a tangible glimmer of hope that a therapy to fix the heart itself may finally be within reach.